{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:09:29Z","timestamp":1778602169200,"version":"3.51.4"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2025-0218_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This multicentre retrospective study aimed to characterise progression-free survival (PFS) patterns and identify clinicopathological factors associated with disease progression in childhood and adolescent differentiated thyroid carcinoma (caDTC) patients with intermediate-to high-risk persistent disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0218_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients underwent initial treatment comprising total or near-total thyroidectomy, followed by radioiodine therapy and thyroid-stimulating hormone suppression. Univariate analysis using the log-rank test was performed to evaluate prognostic factors associated with PFS in caDTC patients. The median follow-up duration was 56.1\u00a0months (range: 15\u2013112\u00a0months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0218_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 1-, 3-, and 5-year PFS rates among intermediate- and high-risk caDTC patients with persistent disease were 82\u202f, 55, and 32\u202f%, respectively. The median PFS in the structural\/functional persistent disease (S\/FPD) group was significantly shorter than that in the biochemical persistent disease group (21.5 vs. 51.0\u00a0months, p&lt;0.001). High-risk American Thyroid Association (ATA) recurrence risk stratification, stimulated thyroglobulin (sTg) levels\u00a0\u2265\u00a032.9\u202fng\/mL, and S\/FPD response to initial radioiodine therapy (RIT) were significantly associated with poor PFS. The optimal sTg cut-off value for predicting S\/FPD status was 32.9\u202fng\/mL, with an area under the receiver operating characteristic curve of 0.76. Sensitivity and specificity were 68 and 88\u202f%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0218_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among caDTC patients with intermediate-to high-risk persistent disease, those with high-risk ATA recurrence stratification, sTg levels\u00a0\u2265\u00a032.9\u202fng\/mL, and S\/FPD response to initial RIT might require more aggressive treatment and closer clinical surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2025-0218","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:30:13Z","timestamp":1763382613000},"page":"1310-1316","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic analysis of persistent disease in medium-to high-risk children and adolescents with differentiated thyroid carcinoma"],"prefix":"10.1515","volume":"38","author":[{"given":"Huanxin","family":"Liang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University , Nanning , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsi","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University , Nanning , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiao","family":"Wei","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University , Nanning , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhong","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University , Nanning , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"2026051215122196462_j_jpem-2025-0218_ref_001","doi-asserted-by":"crossref","unstructured":"Guo, K, Qian, K, Shi, Y, Sun, T, Chen, L, Mei, D, et al.. Clinical and molecular characterizations of papillary thyroid cancer in children and young adults: a multicenter retrospective study. Thyroid: Off J Am Thyroid Assoc 2021;31:1693\u2013706. https:\/\/doi.org\/10.1089\/thy.2021.0003.","DOI":"10.1089\/thy.2021.0003"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_002","doi-asserted-by":"crossref","unstructured":"Zanella, AB, Scheffel, RS, Weinert, L, Dora, JM, Maia, AL. New insights into the management of differentiated thyroid carcinoma in children and adolescents (review). Int J Oncol 2021;58. https:\/\/doi.org\/10.3892\/ijo.2021.5193.","DOI":"10.3892\/ijo.2021.5193"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_003","doi-asserted-by":"crossref","unstructured":"Banik, GL, Shindo, ML, Kraimer, KL, Manzione, KL, Reddy, A, Kazahaya, K, et al.. Prevalence and risk factors for multifocality in pediatric thyroid cancer. JAMA Otolaryngol Head Neck Surg 2021;147:1100\u20136. https:\/\/doi.org\/10.1001\/jamaoto.2021.3077.","DOI":"10.1001\/jamaoto.2021.3077"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_004","doi-asserted-by":"crossref","unstructured":"Cistaro, A, Quartuccio, N, Garganese, MC, Villani, MF, Altini, C, Pizzoferro, M, et al.. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study. Eur J Nucl Med Mol Imag 2022;49:1374\u201385. https:\/\/doi.org\/10.1007\/s00259-021-05586-8.","DOI":"10.1007\/s00259-021-05586-8"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_005","doi-asserted-by":"crossref","unstructured":"Slack, JCC, Hollowell, M, Barletta, JAA. Thyroid nodules and follicular cell-derived thyroid carcinomas in children. Endocr Pathol 2023;34:165\u201375. https:\/\/doi.org\/10.1007\/s12022-023-09764-2.","DOI":"10.1007\/s12022-023-09764-2"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_006","doi-asserted-by":"crossref","unstructured":"Tuli, G, Munarin, J, Matarazzo, P, Marino, A, Corrias, A, Palestini, N, et al.. Clinical features of thyroid cancer in paediatric age. Experience of a tertiary centre in the 2000\u20132020 period. Endocrine 2023;81:322\u20139. https:\/\/doi.org\/10.1007\/s12020-023-03366-y.","DOI":"10.1007\/s12020-023-03366-y"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_007","doi-asserted-by":"crossref","unstructured":"Lee, KA, Sharabiani, MTA, Tumino, D, Wadsley, J, Gill, V, Gerrard, G, et al.. Differentiated thyroid cancer in children: a UK multicentre review and review of the literature. Clin Oncol 2019;31:385\u201390. https:\/\/doi.org\/10.1016\/j.clon.2019.02.005.","DOI":"10.1016\/j.clon.2019.02.005"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_008","doi-asserted-by":"crossref","unstructured":"Webb, RC, Howard, RS, Stojadinovic, A, Gaitonde, DY, Wallace, MK, Ahmed, J, et al.. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J\u00a0Clin Endocrinol Metabol 2012;97:2754\u201363. https:\/\/doi.org\/10.1210\/jc.2012-1533.","DOI":"10.1210\/jc.2012-1533"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_009","doi-asserted-by":"crossref","unstructured":"Parvathareddy, SK, Siraj, AKK, Annaiyappanaidu, P, Siraj, N, Haqawi, W, Al-Sobhi, SSS, et al.. Tumor size is an independent negative prognostic factor for event free survival in children with differentiated thyroid cancer. Front Endocrinol 2022;13. https:\/\/doi.org\/10.3389\/fendo.2022.979054.","DOI":"10.3389\/fendo.2022.979054"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_010","doi-asserted-by":"crossref","unstructured":"Wang, C, Lu, G, Li, Y, Liu, X, Wang, G, Lu, C, et al.. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy. Front Endocrinol 2023;14. https:\/\/doi.org\/10.3389\/fendo.2023.1217092.","DOI":"10.3389\/fendo.2023.1217092"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_011","unstructured":"Expert Committee of Nuclear Medicine CsoCO, Expert Committee of Thyroid Cancer CsoCO, Committee of Thyroid Disease Society CIEaPAfMaHC, Committee of Thyroid Disease Prevention and Treatment Society CPCPA. Expert consensus on management of differentiated thyroid carcinoma in children and adolescents (2022 edition). CHINA ONCOLOGY 2022;32:451\u201368."},{"key":"2026051215122196462_j_jpem-2025-0218_ref_012","doi-asserted-by":"crossref","unstructured":"Francis, GL, Waguespack, SG, Bauer, AJ, Angelos, P, Benvenga, S, Cerutti, JM, et al.. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid: Off J Am Thyroid Assoc 2015;25:716\u201359. https:\/\/doi.org\/10.1089\/thy.2014.0460.","DOI":"10.1089\/thy.2014.0460"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_013","doi-asserted-by":"crossref","unstructured":"Zampella, E, Piscopo, L, Manganelli, M, Volpe, F, Nappi, C, Gaudieri, V, et al.. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer. Endocrine 2023;80:612\u20138. https:\/\/doi.org\/10.1007\/s12020-023-03309-7.","DOI":"10.1007\/s12020-023-03309-7"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_014","doi-asserted-by":"crossref","unstructured":"Ajdari, SE, Shafiei, B, Motazedian, M, Qutbi, M, Naeilzadeh, P, Asli, IN, et al.. Shifting paradigms in the management of pediatric differentiated thyroid cancer from static to dynamic risk stratification: a step forward toward precision medicine dynamic risk stratification and pediatric thyroid cancer. Nuklearmedizin-Nuclear Med 2019;58:249\u201357. https:\/\/doi.org\/10.1055\/a-0895-4997.","DOI":"10.1055\/a-0895-4997"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_015","doi-asserted-by":"crossref","unstructured":"Zanella, AB, Scheffel, RS, Nava, CF, Golbert, L, de Souza Meyer, EL, Punales, M, et al.. Dynamic risk stratification in the Follow-Up of children and adolescents with differentiated thyroid cancer. Thyroid: Off J Am Thyroid Assoc 2018;28:1285\u201392. https:\/\/doi.org\/10.1089\/thy.2018.0075.","DOI":"10.1089\/thy.2018.0075"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_016","doi-asserted-by":"crossref","unstructured":"Qu, Y, Huang, R, Li, L. Clinical analysis of the factors that influence disease progression of differentiated thyroid carcinoma in children. J\u00a0Paediatr Child Health 2017;53:903\u20137. https:\/\/doi.org\/10.1111\/jpc.13569.","DOI":"10.1111\/jpc.13569"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_017","doi-asserted-by":"crossref","unstructured":"Massimino, M, Evans, DB, Podda, M, Spinelli, C, Collini, P, Pizzi, N, et al.. Thyroid cancer in adolescents and young adults. Pediatr Blood Cancer 2018;65. https:\/\/doi.org\/10.1002\/pbc.27025.","DOI":"10.1002\/pbc.27025"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_018","doi-asserted-by":"crossref","unstructured":"Markovina, S, Grigsby, PW, Schwarz, JK, DeWees, T, Moley, JF, Siegel, BA, et al.. Treatment approach, surveillance, and outcome of well-differentiated thyroid cancer in childhood and adolescence. Thyroid: Official J Am Thyroid Assoc 2014;24:1121\u20136. https:\/\/doi.org\/10.1089\/thy.2013.0297.","DOI":"10.1089\/thy.2013.0297"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_019","doi-asserted-by":"crossref","unstructured":"Wang, C, Li, Y, Wang, G, Liu, X, Zhang, Y, Lu, C, et al.. Prognostic factors in children and adolescents with differentiated thyroid cancer treated with total thyroidectomy and radioiodine therapy: a retrospective two-center study from China. Front Endocrinol 2024;15. https:\/\/doi.org\/10.3389\/fendo.2024.1419141.","DOI":"10.3389\/fendo.2024.1419141"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_020","doi-asserted-by":"crossref","unstructured":"Javan, FN, Askari, E, Shafiei, S, Roshanravan, V, Aghaei, A, Ayati, N, et al.. The prognostic power of preablation stimulated thyroglobulin in children with differentiated thyroid cancer. Endocr Pract 2024;30:209\u201317. https:\/\/doi.org\/10.1016\/j.eprac.2023.12.005.","DOI":"10.1016\/j.eprac.2023.12.005"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_021","doi-asserted-by":"crossref","unstructured":"Alves-Junior, PAG, Barreto, MCA, de Andrade, FA, Bulzico, DA, Corbo, R, Vaisman, F. Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients. Endocrine 2024;84:1081\u20137. https:\/\/doi.org\/10.1007\/s12020-024-03691-w.","DOI":"10.1007\/s12020-024-03691-w"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_022","doi-asserted-by":"crossref","unstructured":"Parvathareddy, SK, Siraj, AK, Annaiyappanaidu, P, Siraj, N, Al-Rasheed, M, Al-Haqawi, W, et al.. Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia. Front Endocrinol 2023;14. https:\/\/doi.org\/10.3389\/fendo.2023.1228049.","DOI":"10.3389\/fendo.2023.1228049"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_023","doi-asserted-by":"crossref","unstructured":"Klain, M, Zampella, E, Manganelli, M, Gaudieri, V, Nappi, C, D\u2019Antonio, A, et al.. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine 2021;71:378\u201384. https:\/\/doi.org\/10.1007\/s12020-020-02379-1.","DOI":"10.1007\/s12020-020-02379-1"},{"key":"2026051215122196462_j_jpem-2025-0218_ref_024","doi-asserted-by":"crossref","unstructured":"Zanella, A, Scheffel, RS, Pasa, MW, Dora, JM, Maia, AL. Role of postoperative stimulated thyroglobulin as prognostic factor for differentiated thyroid cancer in children and adolescents. Thyroid official J Am Thyroid Assoc 2017;27:787\u201392. https:\/\/doi.org\/10.1089\/thy.2016.0559.","DOI":"10.1089\/thy.2016.0559"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0218\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0218\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:16:34Z","timestamp":1778598994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0218\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,13]]},"published-print":{"date-parts":[[2025,12,17]]}},"alternative-id":["10.1515\/jpem-2025-0218"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0218","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}